{"id":36533,"date":"2021-08-02T17:06:00","date_gmt":"2021-08-02T15:06:00","guid":{"rendered":"https:\/\/www.ipsen.com\/?post_type=press_release&#038;p=36533"},"modified":"2023-08-31T07:37:24","modified_gmt":"2023-08-31T05:37:24","slug":"ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/","title":{"rendered":"Ipsen conclut une collaboration exclusive avec Exicure dans les maladies neurod\u00e9g\u00e9n\u00e9ratives rares"},"content":{"rendered":"<ul>\n<li style=\"margin-bottom: 3px\">Ipsen obtient une option de licence exclusive pour les acides nucl\u00e9iques sph\u00e9riques (SNAsTM), actuellement en cours d\u2019\u00e9valuation dans la maladie de Huntington et le syndrome d\u2019Angelman<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom: 3px\">Exicure sera responsable de la recherche et de certaines activit\u00e9s de d\u00e9veloppement pr\u00e9clinique. S\u2019il exerce son option pour les deux programmes, Ipsen sera responsable des phases plus avanc\u00e9es de d\u00e9veloppement et de la commercialisation \u00e0 l\u2019\u00e9chelle mondiale des m\u00e9dicaments<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom: 3px\">Exicure recevra un paiement initial de 20 millions de dollars. La soci\u00e9t\u00e9 pourra en outre recevoir jusqu\u2019\u00e0 1 milliard de dollars provenant de commissions li\u00e9es \u00e0 l\u2019exercice de l\u2019option et de paiements d\u2019\u00e9tape si Ipsen d\u00e9cide d\u2019exercer son option pour les deux programmes, ainsi que des redevances progressives<\/li>\n<\/ul>\n<p><b>Paris (France), et Chicago, IL, Cambridge, MA (\u00c9tats-Unis) Lundi 2 ao\u00fbt 2021 \u2013\u00a0<\/b>Ipsen (Euronext: IPN\u00a0; ADR\u00a0: IPSEY) et Exicure Inc. (NASDAQ\u00a0: XCUR) ont sign\u00e9 un accord de collaboration exclusif pour la recherche, le d\u00e9veloppement et la commercialisation de nouveaux acides nucl\u00e9iques sph\u00e9riques (SNA) dans le traitement potentiel de la maladie de Huntington et du syndrome d\u2019Angelman.<\/p>\n<p>Les oligonucl\u00e9otides sont des structures synth\u00e9tiques d\u2019acides nucl\u00e9iques qui peuvent \u00eatre utilis\u00e9es pour moduler l\u2019expression des g\u00e8nes via divers processus, y compris l\u2019activation, l\u2019inhibition et la modulation de l\u2019\u00e9pissage des g\u00e8nes. Ces mol\u00e9cules ont d\u00e9montr\u00e9 leur potentiel dans de nombreux domaines th\u00e9rapeutiques.1\u00a0La distribution des oligonucl\u00e9otides vers les organes et tissus cibles, y compris dans le cerveau, reste un obstacle majeur \u00e0 leur utilisation1,2. Les SNA d\u2019Exicure fournissent des propri\u00e9t\u00e9s chimiques et biochimiques distinctes aux oligonucl\u00e9otides. Dans les mod\u00e8les pr\u00e9cliniques, il a \u00e9t\u00e9 d\u00e9montr\u00e9 que les SNA am\u00e9liorent la p\u00e9n\u00e9tration cellulaire, la biodistribution et la persistance des oligonucl\u00e9otides dans les organes3,4. Ceci peut potentiellement am\u00e9liorer l\u2019administration de m\u00e9dicaments dans des tissus cibles auparavant inaccessibles, y compris des r\u00e9gions profondes du cerveau\u00a05,6<sup>]<\/sup>.<\/p>\n<p>Philippe Lopes-Fernandes, Chief Business Officer d\u2019Ipsen, a d\u00e9clar\u00e9\u00a0: \u00ab\u00a0<em>Les neurosciences sont profond\u00e9ment ancr\u00e9es au sein d\u2019Ipsen et constituent un moteur strat\u00e9gique de notre activit\u00e9.<\/em>\u00a0<em>Nous sommes ravis de nous associer \u00e0 Exicure afin de poursuivre le d\u00e9veloppement d\u2019options th\u00e9rapeutiques exp\u00e9rimentales pour la maladie de Huntington et le syndrome d\u2019Angelman, deux pathologies pr\u00e9sentant d\u2019importants besoins non satisfaits.<\/em>\u00a0<em>Cette collaboration marque une \u00e9tape importante dans les efforts entrepris pour r\u00e9aliser pleinement le potentiel de cette nouvelle technologie. Elle r\u00e9unira l\u2019expertise d\u2019Exicure et l\u2019exp\u00e9rience historique d\u2019Ipsen en neurosciences.<\/em>\u00a0<em>Aux c\u00f4t\u00e9s d\u2019Exicure, nous approfondirons notre engagement envers les personnes atteintes de maladies neurologiques dans le monde.<\/em>\u00a0\u00bb<\/p>\n<p>\u00ab<em>\u00a0Nous sommes ravis de nous associer \u00e0 Ipsen, un groupe leader au niveau mondial dot\u00e9 d\u2019une solide expertise et engag\u00e9 dans le d\u00e9veloppement de traitements pour les patients atteints de maladies neurologiques rares,<\/em>\u00a0\u00bb a d\u00e9clar\u00e9 David Giljohann, Ph.D., Directeur g\u00e9n\u00e9ral d\u2019Exicure, Inc. \u00ab\u00a0<em>En collaboration avec Ipsen, nous avons l\u2019opportunit\u00e9 de mettre \u00e0 profit notre technologie pour traiter la maladie de Huntington et le syndrome d\u2019Angelman, deux indications qui n\u00e9cessitent une p\u00e9n\u00e9tration profonde dans le cerveau et des avanc\u00e9es technologiques pouss\u00e9es pour atteindre des cibles auparavant difficiles \u00e0 traiter.<\/em>\u00a0<em>Nous pensons que notre plateforme, gr\u00e2ce \u00e0 sa capacit\u00e9 de p\u00e9n\u00e9tration profonde et \u00e0 la persistance de l\u2019effet du m\u00e9dicament, permettra \u00e0 Exicure et \u00e0 Ipsen de surmonter les d\u00e9fis pos\u00e9s par les oligonucl\u00e9otides de premi\u00e8re g\u00e9n\u00e9ration et d\u2019apporter de nouveaux m\u00e9dicaments \u00e0 des patients qui ne disposent d\u2019aucune option \u00e0 ce jour.<\/em>\u00a0\u00bb<\/p>\n<p>Dans le cadre de cet accord, Ipsen b\u00e9n\u00e9ficiera d\u2019options exclusives de licence pour des traitements bas\u00e9s sur les SNA \u00e0 travers deux programmes de collaboration sur la maladie de Huntington et le syndrome d\u2019Angelman. Ipsen versera \u00e0 Exicure un paiement initial en esp\u00e8ces de 20 millions de dollars \u00e0 la cl\u00f4ture et Exicure sera responsable de la recherche et de certaines activit\u00e9s de d\u00e9veloppement pr\u00e9clinique. S\u2019il exerce son option, Ipsen sera responsable des phases plus avanc\u00e9es de d\u00e9veloppement et de la commercialisation des produits sous licence. Ipsen verserait \u00e0 Exicure une commission en cas d\u2019exercice de l\u2019option. Outre des paiements li\u00e9s \u00e0 l\u2019atteinte d\u2019\u00e9tapes de d\u00e9veloppement, de r\u00e9glementation et de commercialisation. Exicure recevra un paiement initial de 20 millions de dollars. La soci\u00e9t\u00e9 pourra en outre recevoir jusqu\u2019\u00e0 1 milliard de dollars provenant de commissions li\u00e9es \u00e0 l\u2019exercice de l\u2019option et de paiements d\u2019\u00e9tape si Ipsen d\u00e9cide d\u2019exercer son option pour les deux programmes, ainsi que des redevances progressives.<\/p>\n<ol>\n<li style=\"margin-bottom: 3px\">Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery.\u00a0<em>Nature Reviews Drug Discovery<\/em>\u00a02020;19:673\u2013694. Available here:\u00a0<a title=\"\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZJPuIZo6dtMSGbaLWKOMrREeqPk4D-fJ1bKT4ewZuFw8rjswUL8e2gzJk3kDyOSk3O8dtHjM3zJlgNUpV6mWvyEmPp86_hVWP6z_sh-MDaO7JsAfJDI_uTSpGYnve4Ef2cD0nWyYK_V39MRyuBUJzFGb6q8d_ZfubBXCXJK4J6c=\" target=\"_blank\" rel=\"nofollow noopener\"><b>https:\/\/www.nature.com\/articles\/s41573-020-0075-7<\/b><\/a><\/li>\n<li style=\"margin-bottom: 3px\">Crawford L, Rosch J, Putnam D. Concepts, technologies, and practices for drug delivery past the blood\u2013brain barrier to the central nervous system.\u00a0<em>Journal of Controlled Release.<\/em>\u00a02016;240: 251-266. Available here:\u00a0<a title=\"\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZJPuIZo6dtMSGbaLWKOMrXNkVFeRFgqW7xTExWm3elsXtRE2YdcKuqoUaQYwJzF2JpuM1UBzllCfVUfYU5iX7pro-I98RkMen3veAt2QpPVjDEgCloCRLJpTBuG7Jq8er5zr9ZWweQRZIf6amZBLfxj0MXIzZZlTAHXBHP331MAS60OoBQN6cYrPNaJ18b61tu1FSGBeqmcv9CTLn5bWW-MkFwfsWfhQSm0qAI0iO_V4qYM_UOjxK1BhFR6h78X9e_p1Yck7lVdYSeQmZqKquQ==\" target=\"_blank\" rel=\"nofollow noopener\"><b>https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168365915302923?via%3Dihub#bb0020<\/b><\/a><\/li>\n<li style=\"margin-bottom: 3px\"><a title=\"\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZJPuIZo6dtMSGbaLWKOMra05SLZf9rDB9BX3QJmlMnN7ee6AmuYbnKAYoYmIN9cB5j6NrMpXuskOIX6ulgXkgSfYqmjEVtORGkrLDUI0StX0X9uWhBr1J-g130kj3UylFC-M5o10EOAOLqF-3CFgyVhdyoaM1cT5bSsJFI8vzXz4JorH5cj1bWxEtbT2M0nC2-gPx8eo4XRQRAqaZZHzo0uMXgm_PpNLuzf9ud6p9prkCNGex631GXUFkrLhv78a1Vg4Oy12RUpBeXIzQGNx9PcRkE6xtKxBjees1m-MIpgow_upCp5k7rvUhN2CVvUwtH2l7PO6-ykODWIw4ZwkAUD1Lf187aQVFt-cNzt8Tlc9WCZuc_XOTkhofweWWM_70c5Te87xD-PpL3PjbpazGtk15gX10n_AanlKjM1cLt25nAW-gFq0GakAN7B3fJ1jnDUHli3tGTwYt8V0UKbeFO1GDqviseWAB9UT_BiqPYjLpVK__6Vip8WGw3ayZZqi\" target=\"_blank\" rel=\"nofollow noopener\"><b>https:\/\/investors.exicuretx.com\/news\/news-details\/2019\/Exicure-Announces-Preclinical-Data-Supporting-Development-of-SNA-Technology-in-the-Central-Nervous-System\/default.aspx<\/b><\/a><\/li>\n<li style=\"margin-bottom: 3px\"><a title=\"\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZJPuIZo6dtMSGbaLWKOMrSH7v3cUxozj5MVgR_6IdTTceE3dPonnc-qAwGqkY5ZEAbYi3K3Ww6fzuPdtIi_C4R3nLg5s4XkGoaXlFQfwsQqJLsNqpNVoulrp10yVB2ne1Bcev2EviibxFGQhmluhKQNJ5lC3r1TmOMzDEGOM4YJWDyMjFzl97h9uys9yTijV0x9D9IvMnUxp7iLz7AHRS8S85hcB0_jTfX7K_nlVMkQFtyMEp6estluebMjLWZsBbK5Ecwfv12nQM9GnL67bBlXnndKbQm8lRHt09jw_rso=\" target=\"_blank\" rel=\"nofollow noopener\"><b>https:\/\/s1.q4cdn.com\/907903764\/files\/doc_news\/archive\/b984683d-76f4-4759-9add-d2c65150ebb6.pdf<\/b><\/a><\/li>\n<li style=\"margin-bottom: 3px\">Rosi NL, Giljohann DA, Thaxton S, et al. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 2006;312(5776):1027\u20131030. Available here:\u00a0<a title=\"\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZJPuIZo6dtMSGbaLWKOMraUiJPNRdczqaf3GWEzJtzXvLafc9Hx9TwaDk6R3BkZAiwYYwilvuKqzRvmmdLh729aKmg4AWxDK3JX-TzEy9fwr9_nK2h-o0_jeQpBdbGoy4jPCcRScDmqSyDQZUWuFZ4Zhs9Rk9KEAVmrkWu8kC_yBA30UGfiBGIzSJsrl9it_F54_kW00lbBfRllsvVhEIBKz5jOa5QL2hOxMjDGGEDqTT2cCLqKAWF94sQV44E-J3tBNR73YOGQ200E9lvUF4Hka_cRLr2ViKS19vnIvIOkQz-Gu18eWjLfPNqDvXGTloS_oeuZ3atBUdXOaKcByJzJbNIezVwjfiuwhpBCWiSj6Nti62evl1O8YGfu_P7rw\" target=\"_blank\" rel=\"nofollow noopener\"><b>https:\/\/science.sciencemag.org\/content\/312\/5776\/1027?ijkey=8fbfd37b2763498a2658cc0dfaa5dc15df0e81a0&amp;keytype2=tf_ipsecsha<\/b><\/a><\/li>\n<li style=\"margin-bottom: 3px\"><a title=\"\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZJPuIZo6dtMSGbaLWKOMrW2-9Qojv4PRu_hz_7GdeT75fW3uu9aCYPBTSSLN_eynP_ITLTTNcjA9hW0U3sg306LXywtYzNKhbg67wzy0S3X_Sy9i5b7MXMXl9FsYCs4YOP9VDBTWGamODt7rP4bxyKe7tqDmxcDoM1G3qUYiepjU0mQqhc6wQQGanHLnBS_KdrqMto2N_CJY2G7YD9KXHsBt3ZSTIgiUtvmDWMLkgroE1K2O1dIMIOAQlipJfFZs\" target=\"_blank\" rel=\"nofollow noopener\"><b>https:\/\/www.news-medical.net\/life-sciences\/What-is-an-Oligonucleotide.aspx<\/b><\/a><\/li>\n<\/ol>\n<p id=\"gnw_attachments_section-header\"><strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li><a title=\"Ipsen-Collaboration-Exicure-2-Aout-2021\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=ggDSOYABwk7gvk0sNVEe1ininmwUnXtw6hILE5DwCYhA1REm-EFMXOpIFGBO6xejM52tb6k-X-wDgrFp7KsPZbch1Alf1TR-zK0SvFV8TcpB3NDQTwNrGmY6C1ZYqo81EDl2uPA8cc4-0WGfstO_uK1ak6izMusKsnfW8OTo_Jlo2gjM_TEC_7Yq6ul2RUQRNnPH4S3W5uC3NVGilTA94w==\" target=\"_blank\" rel=\"nofollow noopener\">Ipsen-Collaboration-Exicure-2-Aout-2021<\/a><\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/OGJmMTM2ZjEtZDdmZC00NjQ3LWE3YWItN2RhM2U3NDFkMTQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1233,3556,3563,3562],"tags":[],"class_list":["post-36533","press_release","type-press_release","status-publish","hentry","category-pressrelease-fr","category-corporate-pressrelease-fr","category-rare-diseases-pressrelease-fr","category-partnering-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen conclut une collaboration exclusive avec Exicure dans les maladies neurod\u00e9g\u00e9n\u00e9ratives rares<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen conclut une collaboration exclusive avec Exicure dans les maladies neurod\u00e9g\u00e9n\u00e9ratives rares\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-31T05:37:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/OGJmMTM2ZjEtZDdmZC00NjQ3LWE3YWItN2RhM2U3NDFkMTQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\"},\"headline\":\"Ipsen conclut une collaboration exclusive avec Exicure dans les maladies neurod\u00e9g\u00e9n\u00e9ratives rares\",\"datePublished\":\"2021-08-02T15:06:00+00:00\",\"dateModified\":\"2023-08-31T05:37:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/\"},\"wordCount\":956,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/OGJmMTM2ZjEtZDdmZC00NjQ3LWE3YWItN2RhM2U3NDFkMTQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"articleSection\":[\"Communiqu\u00e9 de presse\",\"Corporate\",\"Maladies rares\",\"Partenariat\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/\",\"name\":\"Ipsen conclut une collaboration exclusive avec Exicure dans les maladies neurod\u00e9g\u00e9n\u00e9ratives rares\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/OGJmMTM2ZjEtZDdmZC00NjQ3LWE3YWItN2RhM2U3NDFkMTQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2021-08-02T15:06:00+00:00\",\"dateModified\":\"2023-08-31T05:37:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/OGJmMTM2ZjEtZDdmZC00NjQ3LWE3YWItN2RhM2U3NDFkMTQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/OGJmMTM2ZjEtZDdmZC00NjQ3LWE3YWItN2RhM2U3NDFkMTQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen conclut une collaboration exclusive avec Exicure dans les maladies neurod\u00e9g\u00e9n\u00e9ratives rares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen conclut une collaboration exclusive avec Exicure dans les maladies neurod\u00e9g\u00e9n\u00e9ratives rares","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen conclut une collaboration exclusive avec Exicure dans les maladies neurod\u00e9g\u00e9n\u00e9ratives rares","og_url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/","og_site_name":"Global","article_modified_time":"2023-08-31T05:37:24+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/OGJmMTM2ZjEtZDdmZC00NjQ3LWE3YWItN2RhM2U3NDFkMTQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0"},"headline":"Ipsen conclut une collaboration exclusive avec Exicure dans les maladies neurod\u00e9g\u00e9n\u00e9ratives rares","datePublished":"2021-08-02T15:06:00+00:00","dateModified":"2023-08-31T05:37:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/"},"wordCount":956,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/OGJmMTM2ZjEtZDdmZC00NjQ3LWE3YWItN2RhM2U3NDFkMTQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","articleSection":["Communiqu\u00e9 de presse","Corporate","Maladies rares","Partenariat"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/","url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/","name":"Ipsen conclut une collaboration exclusive avec Exicure dans les maladies neurod\u00e9g\u00e9n\u00e9ratives rares","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/OGJmMTM2ZjEtZDdmZC00NjQ3LWE3YWItN2RhM2U3NDFkMTQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2021-08-02T15:06:00+00:00","dateModified":"2023-08-31T05:37:24+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/OGJmMTM2ZjEtZDdmZC00NjQ3LWE3YWItN2RhM2U3NDFkMTQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/OGJmMTM2ZjEtZDdmZC00NjQ3LWE3YWItN2RhM2U3NDFkMTQ3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-conclut-une-collaboration-exclusive-avec-exicure-dans-les-maladies-neurodegeneratives-rares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen conclut une collaboration exclusive avec Exicure dans les maladies neurod\u00e9g\u00e9n\u00e9ratives rares"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":2,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36533\/revisions"}],"predecessor-version":[{"id":36535,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36533\/revisions\/36535"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=36533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=36533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=36533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}